Novartis Signs Worldwide License Agreement with Forendo Pharma to Discover Therapies Targeting Chronic Liver Diseases

 Novartis Signs Worldwide License Agreement with Forendo Pharma to Discover Therapies Targeting Chronic Liver Diseases

Novartis Signs Worldwide License Agreement with Forendo Pharma to Discover Therapies Targeting Chronic Liver Diseases

Shots:

  • Forendo to receive up front, equity investment, development, regulatory and commercial milestones with royalties on sales. Novartis to fund the research activities and will be responsible for development, manufacturing & commercialization of novel therapies
  • Forendo has its expertise in an enzyme family called HSD17B (17-beta-hydroxysteroid dehydrogenase) responsible for regulating hormone action with its lead candidate, FOR-6219 currently being evaluated in P-I clinical study for endometriosis
  • With the collaboration, Novartis acknowledges Forendo’s core capabilities and the scope of its enzyme family in other therapeutic areas in addition to women’s health

Source 1, Source 2 to­ read full press release/ article | Ref: GlobeNewswire, PRNewswire | Image: Forendo Pharma

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post